Table of Contents

 

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2014

 

OR

 

o  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 001-35299

 

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

Ireland

 

98-1007018

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

Connaught House

1 Burlington Road

Dublin 4, Ireland

(Address of principal executive offices)

 

+ 353-1-772-8000

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files): Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer x

 

Accelerated filer o

 

 

 

Non-accelerated filer o

 

Smaller reporting company o

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes o No x

 

The number of the registrant’s ordinary shares, $0.01 par value, outstanding as of July 25, 2014 was 145,827,889 shares.

 

 

 



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2014

 

 

 

Page No.

PART I - FINANCIAL INFORMATION

 

Item 1.

Condensed Consolidated Financial Statements (unaudited):

 

Condensed Consolidated Balance Sheets — June 30, 2014 and December 31, 2013

5

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income — For the Three and Six Months Ended June 30, 2014 and 2013

6

Condensed Consolidated Statements of Cash Flows — For the Six Months Ended June 30, 2014 and 2013

7

Notes to Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

27

Item 4.

Controls and Procedures

27

 

 

 

PART II - OTHER INFORMATION

 

Item 1.

Legal Proceedings

28

Item 1A.

Risk Factors

28

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

28

Item 5.

Other Information

28

Item 6.

Exhibits

28

Signatures

29

Exhibit Index

 

Ex-31.1 Section 302 Certification of Chief Executive Officer

 

Ex-31.2 Section 302 Certification of Chief Financial Officer

 

Ex-32.1 Section 906 Certification of Chief Executive Officer and Chief Financial Officer

 

Ex-101 Instance Document

 

Ex-101 Schema Document

 

Ex-101 Calculation Linkbase Document

 

Ex-101 Labels Linkbase Document

 

Ex-101 Definition Linkbase Document

 

Ex-101 Presentation Linkbase Document

 

 

2



Table of Contents

 

Cautionary Note Concerning Forward-Looking Statements

 

This document contains and incorporates by reference “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these statements can be identified by the use of forward-looking terminology such as “may,” “will,” “could,” “should,” “would,” “expect,” “anticipate,” “continue,” “believe,” “plan,” “estimate,” “intend,” or other similar words. These statements discuss future expectations, and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. Forward-looking statements in this Quarterly Report on Form 10-Q (“Form 10-Q”) include, without limitation, statements regarding:

 

·                  our expectations regarding our financial performance, including revenues, expenses, gross margins, liquidity, capital expenditures and income taxes;

·                  our expectations regarding our products, including the development, regulatory review (including expectations about regulatory approval and regulatory timelines) and therapeutic and commercial scope and potential of such products and the costs and expenses related thereto;

·                  our expectations regarding the initiation, timing and results of clinical trials of our products;

·                  our expectations regarding the competitive landscape, and changes therein, related to our products, including our development programs;

·                  our expectations regarding the financial impact of currency exchange rate fluctuations and valuations;

·                  our expectations regarding future amortization of intangible assets;

·                  our expectations regarding our collaborations and other significant agreements relating to our products, including our development programs;

·                  our expectations regarding the impact of adoption of new accounting pronouncements;

·                  our expectations regarding near-term changes in the nature of our market risk exposures or in management’s objectives and strategies with respect to managing such exposures;

·                  our ability to comply with restrictive covenants of our indebtedness and our ability to fund our debt service obligations; and

·                  our expectations regarding future capital requirements and capital expenditures and our ability to finance our operations and capital requirements.

 

Actual results might differ materially from those expressed or implied by the forward-looking statements contained in this Form 10-Q because these forward-looking statements are subject to risks, assumptions and uncertainties. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Form 10-Q. Except as required by applicable law or regulation, we do not undertake any obligation to update publicly or revise any forward-looking statements in this Form 10-Q, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this Form 10-Q might not occur. For more information regarding the risk and uncertainties of our business, see ‘‘Item 1A—Risk Factors’’ of our Transition Report on Form 10-K for the nine-month period ended December 31, 2013 (the “Transition Report”) and any subsequent reports filed with the Securities and Exchange Commission.

 

Unless otherwise indicated, information contained in this Form 10-Q concerning the disorders targeted by our products and the markets in which we operate is based on information from various third-party sources (including, without limitation, industry publications, medical and clinical journals and studies, surveys and forecasts) as well as our internal research. Our internal research involves assumptions that we have made, which we believe are reasonable, based on data from those and other similar sources and on our knowledge of the markets for our marketed and development products. Our internal research has not been verified by any independent source, and we have not independently verified any third-party information. These projections, assumptions and estimates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in ‘‘Item 1A—Risk Factors’’ of our Transition Report. These and other factors could cause results to differ materially from those expressed in the estimates included in this Form 10-Q.

 

Note Regarding Company

 

Alkermes plc (as used in this report, together with our subsidiaries, “Alkermes,” “the Company,” ‘‘us,’’ ‘‘we,’’ and ‘‘our’’) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on our own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (“CNS”) disorders such as addiction, schizophrenia and depression.

 

3



Table of Contents

 

Note Regarding Trademarks

 

We are the owner of various U.S. federal trademark registrations (®) and registration applications (TM), including LinkeRx® and VIVITROL®. The following are trademarks of the respective companies listed: ABILIFY®— Otsuka Pharmaceutical Co., Ltd.; AMPYRA® and FAMPYRA®—Acorda Therapeutics, Inc.; BYDUREON® and BYETTA®—Amylin Pharmaceuticals, LLC; FOCALIN XR® and RITALIN LA®—Novartis AG; INVEGA® SUSTENNA®, XEPLION®, and RISPERDAL® CONSTA®—Johnson & Johnson Corp. (or its affiliate); MEGACE®—E.R. Squibb & Sons, LLC; TECFIDERA®—Biogen Idec MA Inc.; TRICOR®—Fournier Industrie et Sante Corporation; and ZYPREXA®—Eli Lilly and Company. Other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 10-Q are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

 

4



Table of Contents

 

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements:

 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

 

 

June 30,

 

December 31,

 

 

 

2014

 

2013

 

 

 

(In thousands, except share and per
share amounts)

 

ASSETS

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

Cash and cash equivalents

 

$

188,322

 

$

167,562

 

Investments — short-term

 

450,167

 

194,669

 

Receivables

 

139,316

 

134,154

 

Inventory

 

57,066

 

46,218

 

Prepaid expenses and other current assets

 

52,048

 

27,535

 

Total current assets

 

886,919

 

570,138

 

PROPERTY, PLANT AND EQUIPMENT, NET

 

264,247

 

274,490

 

INTANGIBLE ASSETS — NET

 

509,900

 

537,565

 

GOODWILL

 

92,740

 

92,740

 

INVESTMENTS — LONG-TERM

 

75,405

 

87,764

 

OTHER ASSETS

 

28,381

 

14,891

 

TOTAL ASSETS

 

$

1,857,592

 

$

1,577,588

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts payable and accrued expenses

 

$

93,033

 

$

91,173

 

Long-term debt — current

 

6,750

 

6,750

 

Deferred revenue — current

 

2,377

 

2,974

 

Total current liabilities

 

102,160

 

100,897

 

LONG-TERM DEBT

 

354,382

 

357,543

 

DEFERRED TAX LIABILITIES, NET — LONG-TERM

 

26,122

 

29,169

 

OTHER LONG-TERM LIABILITIES

 

11,596

 

12,580

 

DEFERRED REVENUE — LONG-TERM

 

11,507

 

12,213

 

Total liabilities

 

505,767

 

512,402

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES (Note 16)

 

 

 

 

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

 

Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at June 30, 2014 and December 31, 2013, respectively

 

 

 

Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 146,646,177 and 138,482,571 shares issued; 145,663,941 and 137,792,626 shares outstanding at June 30, 2014 and December 31, 2013, respectively

 

1,464

 

1,382

 

Treasury shares, at cost (982,236 and 689,945 shares at June 30, 2014 and December 31, 2013, respectively)

 

(30,861

)

(17,833

)

Additional paid-in capital

 

1,886,827

 

1,553,337

 

Accumulated other comprehensive (loss) income

 

(2,712

)

10,574

 

Accumulated deficit

 

(502,893

)

(482,274

)

Total shareholders’ equity

 

1,351,825

 

1,065,186

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$

1,857,592

 

$

1,577,588

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

(unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

(In thousands, except per share amounts)

 

REVENUES:

 

 

 

 

 

 

 

 

 

Manufacturing and royalty revenues

 

$

130,366

 

$

119,788

 

$

241,646

 

$

266,707

 

Product sales, net

 

21,595

 

17,379

 

38,674

 

32,005

 

Research and development revenue

 

1,463

 

1,464

 

3,316

 

3,341

 

Total revenues

 

153,424

 

138,631

 

283,636

 

302,053

 

EXPENSES:

 

 

 

 

 

 

 

 

 

Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)

 

43,290

 

45,991

 

82,129

 

93,982

 

Research and development

 

67,207

 

33,462

 

119,347

 

69,262

 

Selling, general and administrative

 

50,663

 

32,933

 

93,213

 

67,612

 

Amortization of acquired intangible assets

 

15,089

 

12,716

 

27,665

 

23,038

 

Restructuring

 

 

 

 

12,300

 

Impairment of long-lived assets

 

 

 

 

3,346

 

Total expenses

 

176,249

 

125,102

 

322,354

 

269,540

 

OPERATING (LOSS) INCOME

 

(22,825

)

13,529

 

(38,718

)

32,513

 

OTHER INCOME (EXPENSE), NET:

 

 

 

 

 

 

 

 

 

Interest income

 

323

 

161

 

834

 

332

 

Interest expense

 

(3,385

)

(3,468

)

(6,741

)

(14,941

)

Gain on sale of investment in Acceleron Pharma Inc.

 

15,296

 

 

15,296

 

 

Gain on sale of property, plant and equipment

 

12,285

 

 

12,285

 

 

Other income (expense), net

 

518

 

(170

)

(1,332

)

14

 

Total other income (expense), net

 

25,037

 

(3,477

)

20,342

 

(14,595

)

INCOME (LOSS) BEFORE INCOME TAXES

 

2,212

 

10,052

 

(18,376

)

17,918

 

INCOME TAX (BENEFIT) PROVISION

 

(1,523

)

2,718

 

2,243

 

7,585

 

NET INCOME (LOSS)

 

$

3,735

 

$

7,334

 

$

(20,619

)

$

10,333

 

 

 

 

 

 

 

 

 

 

 

EARNINGS (LOSS) PER ORDINARY SHARE:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.03

 

$

0.05

 

$

(0.14

)

$

0.08

 

Diluted

 

$

0.02

 

$

0.05

 

$

(0.14

)

$

0.07

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:

 

 

 

 

 

 

 

 

 

Basic

 

144,913

 

134,602

 

144,140

 

133,941

 

Diluted

 

154,300

 

143,369

 

144,140

 

141,822

 

 

 

 

 

 

 

 

 

 

 

COMPREHENSIVE (LOSS) INCOME:

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

3,735

 

$

7,334

 

$

(20,619

)

$

10,333

 

Holding gains (losses), net of tax of $6,174, none, $7,627 and none, respectively

 

4,540

 

(408

)

2,009

 

(265

)

Reclassification of unrealized gains to realized gains

 

(15,296

)

 

(15,296

)

 

COMPREHENSIVE (LOSS) INCOME

 

$

(7,021

)

$

6,926

 

$

(33,906

)

$

10,068

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2014

 

2013

 

 

 

(In thousands)

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

Net (loss) income

 

$

(20,619

)

$

10,333

 

Adjustments to reconcile net (loss) income to cash flows from operating activities:

 

 

 

 

 

Depreciation and amortization

 

47,486

 

42,048

 

Share-based compensation expense

 

32,758

 

16,690

 

Excess tax benefit from share-based compensation

 

(6,984

)

(11,730

)

Impairment of long-lived assets

 

 

3,346

 

(Gain) loss on sale of property, plant and equipment

 

(12,160

)

391

 

(Gain) on sale of investment of Acceleron Pharma Inc.

 

(15,296

)

 

Deferred income taxes

 

(10,664

)

(1,732

)

Loss on debt refinancing transaction

 

 

7,541

 

Prepayment penalty in connection with debt refinancing

 

 

(3,733

)

Other non-cash charges

 

9,965

 

1,169

 

Changes in assets and liabilities:

 

 

 

 

 

Receivables

 

(5,162

)

(10,743

)

Inventory, prepaid expenses and other assets

 

(19,714

)

(1,036

)

Accounts payable and accrued expenses

 

3,693

 

16,929

 

Deferred revenue

 

(1,304

)

(974

)

Other long-term liabilities

 

3,306

 

(448

)

Cash flows provided by operating activities

 

5,305

 

68,051

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

Additions of property, plant and equipment

 

(11,438

)

(11,884

)

Proceeds from the sale of property, plant and equipment

 

14,361

 

125

 

Purchases of investments

 

(433,203

)

(175,619

)

Sales and maturities of investments

 

184,446

 

70,149

 

Cash flows used in investing activities

 

(245,834

)

(117,229

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

Proceeds from the issuance of ordinary shares, net

 

248,406

 

 

Proceeds from the issuance of ordinary shares under share-based compensation arrangements

 

21,821

 

31,926

 

Excess tax benefit from share-based compensation

 

6,984

 

11,730

 

Employee taxes paid related to net share settlement of equity awards

 

(12,546

)

(8,523

)

Principal payments of long-term debt

 

(3,376

)

(5,450

)

Cash flows provided by financing activities

 

261,289

 

29,683

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

20,760

 

(19,495

)

CASH AND CASH EQUIVALENTS — Beginning of period

 

167,562

 

135,892

 

CASH AND CASH EQUIVALENTS — End of period

 

$

188,322

 

$

116,397

 

SUPPLEMENTAL CASH FLOW DISCLOSURE:

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

Purchased capital expenditures included in accounts payable and accrued expenses

 

$

1,491

 

$

1,056

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

7



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited)

 

1. THE COMPANY

 

Alkermes plc (“Alkermes”) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address CNS disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes has a research and development (“R&D”) center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements of the Company for the three and six months ended June 30, 2014 and 2013 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the nine-month transition period ended December 31, 2013 (the “Transition Period”). The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S.”) (commonly referred to as “GAAP”). In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, that are necessary to present fairly the results of operations for the reported periods.

 

These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of Alkermes, which are contained in the Company’s Transition Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission (“SEC”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period, including the Transition Period, or for a full fiscal year.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Alkermes plc and its wholly owned subsidiaries as disclosed in Note 2: Summary of Significant Accounting Policies within Part II, Item 8 of our Transition Report. During the six months ended June 30, 2014, the following wholly owned subsidiaries were added: Alkermes Science Three Limited; Alkermes Science Four Limited; and Alkermes Science Five Limited. Intercompany accounts and transactions have been eliminated.

 

Use of Estimates

 

The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments, litigation and restructuring charges. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

 

Segment Information

 

The Company operates as one business segment, which is the business of developing, manufacturing and commercializing medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious diseases. The Company’s chief decision maker, the Chairman and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit.

 

8



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

New Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

 

In July 2013, the FASB adopted clarifying guidance on the presentation of unrecognized tax benefits when various qualifying tax credits exist. The amendment requires that unrecognized tax benefits be presented on the consolidated balance sheet as a reduction to deferred tax assets created by net operating losses (‘‘NOLs’’) or other tax credits from prior periods that occur in the same taxing jurisdiction. To the extent that the unrecognized tax benefit exceeds these NOLs or other tax credits, it shall be presented as a liability. This update, required to be adopted for all annual periods and interim reporting periods beginning after December 15, 2013, was adopted by the Company on January 1, 2014. The adoption of this standard did not have a material impact on the presentation of the Company’s financial position.

 

In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. Existing GAAP does not contain explicit guidance on how to account for these share-based payments. The new guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Entities have the option of prospectively applying the guidance to awards granted or modified after the effective date or retrospectively applying the guidance to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements. The guidance becomes effective for the Company in its year ending December 31, 2016 and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

 

In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in its year ending December 31, 2017 and early adoption is not permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

 

9



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

3. INVESTMENTS

 

Investments consisted of the following:

 

 

 

 

 

Gross Unrealized

 

 

 

 

 

 

 

 

 

Losses

 

 

 

 

 

Amortized

 

 

 

Less than

 

Greater than

 

Estimated

 

 

 

Cost

 

Gains

 

One Year

 

One Year

 

Fair Value

 

 

 

(In thousands)

 

June 30, 2014

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

U.S. government and agency debt securities

 

$

223,404

 

$

192

 

$

 

$

 

$

223,596

 

Corporate debt securities

 

178,720

 

153

 

(30

)

 

178,843

 

International government agency debt securities

 

46,492

 

37

 

(2

)

 

46,527

 

 

 

448,616

 

382

 

(32

)

 

448,966

 

Money market funds

 

1,201

 

 

 

 

1,201

 

Total short-term investments

 

449,817

 

382

 

(32

)

 

450,167

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

U.S. government and agency debt securities

 

42,082

 

 

(43

)

(13

)

42,026

 

Corporate debt securities

 

25,793

 

 

(17

)

(22

)

25,754

 

International government agency debt securities

 

6,080

 

 

(2

)

 

6,078

 

 

 

73,955

 

 

(62

)

(35

)

73,858

 

Held-to-maturity securities:

 

 

 

 

 

 

 

 

 

 

 

Certificates of deposit

 

1,547

 

 

 

 

1,547

 

Total long-term investments

 

75,502

 

 

(62

)

(35

)

75,405

 

Total investments

 

$

525,319

 

$

382

 

$

(94

)

$

(35

)

$

525,572

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2013

 

 

 

 

 

 

 

 

 

 

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

U.S. government and agency debt securities

 

$

130,669

 

$

80

 

$

(1

)

$

 

$

130,748

 

Corporate debt securities

 

38,614

 

64

 

(30

)

 

38,648

 

International government agency debt securities

 

24,097

 

8

 

(33

)

 

24,072

 

 

 

193,380

 

152

 

(64

)

 

193,468

 

Money market funds

 

1,201

 

 

 

 

1,201

 

Total short-term investments

 

194,581

 

152

 

(64

)

 

194,669

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

8,732

 

21,253

 

 

 

29,985

 

U.S. government and agency debt securities

 

28,503

 

 

(61

)

(3

)

28,439

 

Corporate debt securities

 

20,266

 

 

(30

)

(75

)

20,161

 

International government agency debt securities

 

7,691

 

 

(5

)

 

7,686

 

 

 

65,192

 

21,253

 

(96

)

(78

)

86,271

 

Held-to-maturity securities:

 

 

 

 

 

 

 

 

 

 

 

Certificates of deposit

 

1,493

 

 

 

 

1,493

 

Total long-term investments

 

66,685

 

21,253

 

(96

)

(78

)

87,764

 

Total investments

 

$

261,266

 

$

21,405

 

$

(160

)

$

(78

)

$

282,433

 

 

10



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

The proceeds from the sales and maturities of marketable securities, which were primarily reinvested and resulted in realized gains and losses, were as follows:

 

 

 

Six Months Ended

 

 

 

June 30,

 

(In thousands)

 

2014

 

2013

 

Proceeds from the sales and maturities of marketable securities

 

$

184,446

 

$

70,149

 

Realized gains

 

$

15,304

 

$

46

 

Realized losses

 

$

10

 

$

5

 

 

During the three months ended June 30, 2014, the Company sold its investment in Acceleron Pharma Inc. (“Acceleron”), which consisted of common stock and warrants to purchase the common stock of Acceleron. The Company received net proceeds of $24.0 million and realized a gain of $15.3 million from the sale of this investment. The Company reclassified the gain from accumulated other comprehensive (loss) income to gain on sale of investment in Acceleron in its condensed consolidated Statements of Operations and Comprehensive (Loss) Income.

 

The Company’s available-for-sale and held-to-maturity securities at June 30, 2014 had contractual maturities in the following periods:

 

 

 

Available-for-sale

 

Held-to-maturity

 

 

 

Amortized

 

Estimated

 

Amortized

 

Estimated

 

(In thousands)

 

Cost

 

Fair Value

 

Cost

 

Fair Value

 

Within 1 year

 

$

296,062

 

$

296,166

 

$

1,547

 

$

1,547

 

After 1 year through 5 years

 

226,509

 

226,658

 

 

 

Total

 

$

522,571

 

$

522,824

 

$

1,547

 

$

1,547

 

 

At June 30, 2014, the Company believed that the unrealized losses on its available-for-sale investments were temporary. The investments with unrealized losses consisted primarily of U.S. government and agency debt securities and corporate debt securities. In making the determination that the decline in fair value of these securities was temporary, the Company considered various factors, including but not limited to: the length of time each security was in an unrealized loss position; the extent to which fair value was less than cost; financial condition and near-term prospects of the issuers; and the Company’s intent not to sell these securities and the assessment that it is more likely than not that the Company would not be required to sell these securities before the recovery of their amortized cost basis.

 

The Company’s investment in Civitas Therapeutics, Inc. (“Civitas”) was zero and $2.0 million at June 30, 2014 and December 31, 2013, respectively, which was recorded within “Other Assets” in the accompanying condensed consolidated balance sheets. During the six months ended June 30, 2014, the Company recorded a reduction in its investment in Civitas of $2.0 million, which represented the Company’s proportionate share of Civitas’ net losses for this period.  As the Company’s interest in Civitas has reached zero, the Company will no longer record its proportionate share of Civitas’ net losses until such time as the Company’s share of Civitas’ net income exceeds its share of Civitas’ net losses not recognized during the period the equity method was suspended.

 

11



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

4. FAIR VALUE MEASUREMENTS

 

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

 

 

 

June 30,

 

 

 

 

 

 

 

(In thousands)

 

2014

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

1,201

 

$

1,201

 

$

 

$

 

U.S. government and agency debt securities

 

265,622

 

126,594

 

139,028

 

 

Corporate debt securities

 

204,597

 

 

204,597

 

 

International government agency debt securities

 

52,605

 

 

52,605

 

 

Total

 

$

524,025

 

$

127,795

 

$

396,230

 

$

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

Interest rate swap contract

 

$

(92

)

$

 

$

(92

)

$

 

Total

 

$

(92

)

$

 

$

(92

)

$

 

 

 

 

December 31,

 

 

 

 

 

 

 

(In thousands)

 

2013

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

1,201

 

$

1,201

 

$

 

$

 

U.S. government and agency debt securities

 

159,187

 

63,213

 

95,974

 

 

Corporate debt securities

 

58,809

 

 

58,809

 

 

International government agency debt securities

 

31,758

 

 

31,758

 

 

Equity securities

 

29,985

 

28,459

 

 

1,526

 

Total

 

$

280,940

 

$

92,873

 

$

186,541

 

$

1,526

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

Interest rate swap contract

 

$

(275

)

$

 

$

(275

)

$

 

Total

 

$

(275

)

$

 

$

(275

)

$

 

 

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.

 

There were no transfers of any securities from Level 1 to Level 2 or from Level 2 to Level 1 during the six months ended June 30, 2014. The following table is a rollforward of the fair value of the Company’s investments whose fair value was determined using Level 3 inputs at June 30, 2014:

 

(In thousands)

 

Fair Value

 

Balance, January 1, 2014

 

$

1,526

 

Total unrealized losses included in other comprehensive (loss) income

 

(383

)

Sale of equity securities

 

(1,143

)

Balance, June 30, 2014

 

$

 

 

12



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

During the three months ended June 30, 2014, the Company sold its Level 3 investment, which consisted of warrants to purchase the common stock of Acceleron.

 

The Company’s investments in U.S. government and agency debt securities, international government agency debt securities and corporate debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

 

The Company entered into an interest rate swap agreement in September 2011, which is described in greater detail in Note 11, Derivative Instruments. The fair value of the Company’s interest rate swap agreement was based on an income approach, which excludes accrued interest, and takes into consideration then-current interest rates and the then-current creditworthiness of the Company or the counterparty, as applicable.

 

The carrying amounts reflected in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term nature. The fair value of the remaining financial instruments not currently recognized at fair value on the Company’s condensed consolidated balance sheets consisted of the $300.0 million, seven-year term loan bearing interest at LIBOR plus 2.75% with a LIBOR floor of 0.75% (“Term Loan B-1”) and the $75.0 million, four-year term loan bearing interest at LIBOR plus 2.75%, with no LIBOR floor (“Term Loan B-2” and together with Term Loan B-1, the “Term Loan Facility”). The estimated fair value of these term loans, which was based on quoted market price indications (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future, was as follows at June 30, 2014:

 

 

 

Carrying

 

Estimated

 

(In thousands)

 

Value

 

Fair Value

 

Term Loan B-1

 

$

292,784

 

$

294,013

 

Term Loan B-2

 

$

68,348

 

$

68,438

 

 

5. INVENTORY

 

Inventory is stated at the lower of cost or market value. Cost is determined using the first-in, first-out method. Inventory consisted of the following:

 

 

 

June 30,

 

December 31,

 

(In thousands)

 

2014

 

2013

 

Raw materials

 

$

18,890

 

$

18,410

 

Work in process

 

19,762

 

15,581

 

Finished goods

 

18,414

 

12,227

 

Total inventory

 

$

57,066

 

$

46,218

 

 

13



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

6. PROPERTY, PLANT AND EQUIPMENT

 

Property, plant and equipment consisted of the following:

 

 

 

June 30,

 

December 31,

 

(In thousands)

 

2014

 

2013

 

Land

 

$

8,163

 

$

8,440

 

Building and improvements

 

148,298

 

148,044

 

Furniture, fixture and equipment

 

225,166

 

220,984

 

Leasehold improvements

 

24,000

 

23,980

 

Construction in progress

 

31,699

 

26,688

 

Subtotal

 

437,326

 

428,136

 

Less: accumulated depreciation

 

(173,079

)

(153,646

)

Total property, plant and equipment, net

 

$

264,247

 

$

274,490

 

 

During the three months ended June 30, 2014, the Company sold certain of its land, buildings and equipment at its Athlone, Ireland facility that had a carrying value of $2.2 million in exchange for $17.5 million. $3.0 million of the sale proceeds will remain in escrow pending the completion of certain additional services the Company is obligated to perform, and will be recognized as “Gain on sale of property, plant and equipment” as the services are provided.

 

7. GOODWILL AND INTANGIBLE ASSETS

 

Goodwill and intangible assets consisted of the following:

 

 

 

 

 

June 30, 2014

 

 

 

Weighted

 

Gross

 

Accumulated

 

Net

 

(In thousands)

 

Amortizable Life

 

Carrying Amount

 

Amortization

 

Carrying Amount

 

Goodwill

 

 

 

$

92,740

 

$

 

$

92,740

 

 

 

 

 

 

 

 

 

 

 

Finite-lived intangible assets:

 

 

 

 

 

 

 

 

 

Collaboration agreements

 

12

 

$

499,700

 

$

(102,810

)

$

396,890

 

NanoCrystal technology

 

13

 

74,600

 

(10,760

)

63,840

 

OCR technology

 

12

 

66,300

 

(17,130

)

49,170

 

Total

 

 

 

$

640,600

 

$

(130,700

)

$

509,900

 

 

The Company recorded, as “Amortization of acquired intangible assets” in the accompanying condensed consolidated Statements of Operations and Comprehensive (Loss) Income, $27.7 million and $23.0 million of amortization expense related to its finite-lived intangible assets during the six months ended June 30, 2014 and 2013, respectively, all of which related to cost of goods manufactured and sold. Based on the Company’s most recent analysis, amortization of intangible assets included within its condensed consolidated balance sheet at June 30, 2014 is expected to be approximately $60.0 million, $65.0 million, $70.0 million, $70.0 million and $70.0 million in the years ending December 31, 2014 through 2018, respectively. Although the Company believes such available information and assumptions are reasonable, given the inherent risks and uncertainties underlying its expectations regarding such future revenues, there is the potential for the Company’s actual results to vary significantly from such expectations. If revenues are projected to change, the related amortization of the intangible assets will change in proportion to the change in revenues.

 

14



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consisted of the following:

 

 

 

June 30,

 

December 31,

 

(In thousands)

 

2014

 

2013

 

Accounts payable

 

$

21,261

 

$

19,493

 

Accrued compensation

 

23,196

 

28,101

 

Accrued restructuring

 

8,161

 

7,296

 

Accrued other

 

40,415

 

36,283

 

Total accounts payable and accrued expenses

 

$

93,033

 

$

91,173

 

 

9. RESTRUCTURING

 

On April 4, 2013, the Company approved a restructuring plan at its Athlone, Ireland manufacturing facility consistent with the evolution of the Company’s product portfolio and designed to improve operational performance for the future. The restructuring plan calls for the Company to terminate manufacturing services for certain older products that are expected to no longer be economically practicable to produce due to decreasing demand from its customers resulting from generic competition. The Company expects to continue to generate revenues from the manufacturing of these products through the year ending December 31, 2015.

 

As a result of the termination of these services, the Company also implemented a corresponding reduction in headcount of up to 130 employees. In connection with this restructuring plan, during the twelve months ended March 31, 2013, the Company recorded a restructuring charge of $12.3 million, which consisted of severance and outplacement services. The Company has paid in cash $5.1 million in connection with this restructuring plan and recorded an adjustment of $0.5 million to the restructuring accrual due to changes in foreign currency. Restructuring activity during the six months ended June 30, 2014 was as follows:

 

 

 

Severance and

 

(In thousands)

 

Outplacement Services

 

Balance, January 1, 2014

 

$

10,578

 

Payments

 

(2,804

)

Adjustments

 

(106

)

Balance, June 30, 2014

 

$

7,668

 

 

At June 30, 2014 and December 31, 2013, $7.7 million and $6.8 million, respectively, of this restructuring accrual was included within “Accounts payable and accrued expenses,” and none and $3.8 million, respectively, was included within “Other long-term liabilities” in the accompanying condensed consolidated balance sheets.

 

10. LONG-TERM DEBT

 

Long-term debt consisted of the following:

 

15



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

 

 

June 30,

 

December 31,

 

(In thousands)

 

2014

 

2013

 

Term Loan B-1, due September 25, 2019

 

$

292,784

 

$

294,091

 

Term Loan B-2, due September 25, 2016

 

68,348

 

70,202

 

Total

 

361,132

 

364,293

 

Less: current portion

 

(6,750

)

(6,750

)

Long-term debt

 

$

354,382

 

$

357,543

 

 

11. DERIVATIVE INSTRUMENTS

 

In September 2011, the Company entered into an interest rate swap agreement with Morgan Stanley Capital Services LLC to mitigate the impact of fluctuations in the three-month LIBOR rate at which the Company’s long-term debt bears interest. The interest rate swap agreement became effective in December 2012, expires in December 2014 and has a notional value of $65.0 million. The Company recorded an immaterial loss and a gain of $0.1 million within “Other income (expense), net” due to the change in fair value of this contract during the six months ended June 30, 2014 and 2013, respectively. The fair value and presentation in the condensed consolidated balance sheets for the Company’s interest rate swap was as follows:

 

 

 

 

 

Fair Value

 

(In thousands)

 

Balance Sheet Location

 

June 30, 2014

 

December 31, 2013

 

Liability derivative not designated as a cash flow hedge

 

Other long-term liabilities

 

$

(92

)

$

(275

)

 

12. SHARE-BASED COMPENSATION

 

Share-based compensation expense consisted of the following:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

(In thousands)

 

2014

 

2013

 

2014

 

2013

 

Cost of goods manufactured and sold

 

$

1,770

 

$

1,003

 

$

4,079

 

$

2,074

 

Research and development

 

4,079

 

2,165

 

7,482

 

4,304

 

Selling, general and administrative

 

13,489

 

5,641

 

21,197

 

10,312

 

Total share-based compensation expense

 

$

19,338

 

$

8,809

 

$

32,758

 

$

16,690

 

 

At June 30, 2014 and December 31, 2013, $0.6 million and $0.4 million, respectively, of share-based compensation cost was capitalized and recorded as “Inventory” in the accompanying condensed consolidated balance sheets.

 

13.  SHAREHOLDERS’ EQUITY

 

In January 2014, the Company sold 5,917,160 ordinary shares, $0.01 par value per share, pursuant to its shelf registration statement on Form S-3 at a price of $42.25 per share. The Company received total gross proceeds of $250.0 million, before deducting expenses of $1.6 million associated with the offering.

 

14.  EARNINGS (LOSS) PER SHARE

 

Basic earnings (loss) per ordinary share is calculated based upon net income (loss) available to holders of ordinary shares divided by the weighted average number of shares outstanding. For the calculation of diluted earnings (loss) per ordinary share, the Company uses the weighted average number of ordinary shares outstanding, as adjusted for the effect of potential outstanding shares, including stock options and restricted stock units.

 

16



Table of Contents

 

ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Continued)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

(In thousands)

 

2014

 

2013

 

2014

 

2013

 

Numerator:

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

3,735

 

$

7,334

 

$

(20,619

)

$

10,333

 

Denominator:

 

 

 

 

 

 

 

 

 

Weighted average number of ordinary shares outstanding

 

144,913

 

134,602

 

144,140

 

133,941

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

Stock options

 

8,067

 

7,287

 

 

6,349

 

Restricted stock units

 

1,320

 

1,480

 

 

1,532

 

Dilutive ordinary share equivalents

 

9,387

 

8,767

 

 

7,881

 

Shares used in calculating diluted earnings (loss) per share

 

154,300

 

143,369

 

144,140

 

141,822

 

 

The following potential ordinary equivalent shares have not been included in the net income (loss) per ordinary share calculation because the effect would have been anti-dilutive:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

(In thousands)

 

2014

 

2013

 

2014

 

2013

 

Stock options

 

1,879

 

883

 

9,644

 

516

 

Restricted stock units

 

695

 

 

1,892

 

 

Total

 

2,574

 

883

 

11,536

 

516

 

 

15. INCOME TAXES

 

The Company recorded an income tax benefit of $1.5 million and an income tax provision of $2.2 million for the three and six months ended June 30, 2014, respectively and an income tax provision of $2.7 million and $7.6 million for the three and six months ended June 30, 2013, respectively. The income tax provision in the three and six months ended June 30, 2014 and 2013 primarily relates to U.S. Federal and state taxes on income.

 

The Company records a deferred tax asset or liability based on the difference between the financial statement and tax basis of its assets and liabilities, as measured by enacted jurisdictional tax rates assumed to be in effect when these differences reverse. At June 30, 2014, the Company maintained a valuation allowance against certain of its U.S. and foreign deferred tax assets.  The Company evaluates, at each reporting period, the need for a valuation allowance on its deferred tax assets on a jurisdiction by jurisdiction basis.

 

16. COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. For example, the Company is currently involved in various Paragraph IV lawsuits in the U.S. and other proceedings outside of the U.S. involving its patents in respect of FOCALIN XR, TRICOR, RITALIN LA, MEGACE ES and AMPYRA. The Company is not aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition, cash flows and results of operations.

 

In May 2014, the Company entered into an agreement whereby it is committed to provide up to €7.4 million to a partnership, Fountain Healthcare Partners II, L.P. of Ireland, which was created to carry on the business of investing exclusively in companies and businesses engaged in healthcare, pharmaceutical and life sciences sectors. The Company’s commitment represents approximately 10% of the partnership’s total funding.  At June 30, 2014, the Company had made a payment of $0.5 million, which is included within “Other long-term assets” in the accompanying condensed consolidated balance sheets.

 

17



Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion should be read in conjunction with our condensed consolidated financial statements and related notes beginning on page 5 of this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in our Transition Report, which has been filed with the SEC.

 

Executive Summary

 

Net income for the three months ended June 30, 2014 was $3.7 million, or $0.03 per ordinary share— basic and $0.02 per ordinary share—diluted, as compared to net income of $7.3 million, or $0.05 per ordinary share— basic and diluted, for the three months ended June 30, 2013.  Net loss for the six months ended June 30, 2014 was $20.6 million, or $0.14 per ordinary share— basic and diluted, as compared to net income of $10.3 million, or $0.08 per ordinary share— basic and $0.07 per ordinary share —diluted, for the six months ended June 30, 2013.

 

During the three and six months ended June 30, 2014, we recorded total revenues of $153.4 million and $283.6 million, respectively, as compared to $138.6 million and $302.1 million in the three and six months ended June 30, 2013, respectively. Included in revenue for the six months ended June 30, 2013 was $30.0 million of intellectual property (“IP”) license revenue unrelated to key development programs.

 

Our operating expenses for the three and six months ended June 30, 2014 were $176.2 million and $322.4 million, respectively, reflecting increased investment in our rapidly advancing development pipeline, such as the initiation of the pivotal clinical development program for ALKS 5461, and prelaunch activities for aripiprazole lauroxil. We announced positive phase 3 results for aripiprazole lauroxil in April 2014 and are preparing to submit our New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the third quarter of this year.

 

Also during the six months ended June 30, 2014, we sold approximately 5.9 million ordinary shares, through a registered direct offering, to Invesco Perpetual Income Fund (“IPI Fund”) and the Invesco Perpetual High Income Fund (“IPHI Fund” and together with the IPI Fund, the “Invesco Funds”), for gross proceeds of $250.0 million.

 

Marketed Products

 

We earn manufacturing and/or royalty revenues on net sales from a diversified portfolio of more than 20 products marketed by our partners, and earn revenue on net sales of VIVITROL (naltrexone for extended-release injectable suspension), which is a proprietary product that we manufacture, market and sell in the U.S. Our key marketed products, which are expected to contribute meaningfully to our revenues are discussed below. We expect revenues from our other marketed products, taken together, to decrease in the future due to existing and expected competition from generic manufacturers.

 

RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION

 

RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate our proprietary technologies. They are products of Janssen.

 

RISPERDAL CONSTA uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is exclusively manufactured by us and is marketed and sold by Janssen worldwide. It was first approved for the treatment of schizophrenia in the U.S. in 2003 and in countries in Europe in 2002. The FDA approved RISPERDAL CONSTA as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder in May 2009. RISPERDAL CONSTA is also approved for the maintenance treatment of bipolar I disorder in over 25 other countries worldwide.

 

INVEGA SUSTENNA uses our nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA SUSTENNA was approved for the acute and maintenance treatment of schizophrenia in adults in the U.S. in 2009. Paliperidone palmitate extended-release injectable suspension is also approved in the European Union (“EU”) and other countries worldwide, and is marketed and sold in the EU under the trade name XEPLION. INVEGA SUSTENNA/XEPLION is manufactured and commercialized worldwide by Janssen.

 

AMPYRA/FAMPYRA

 

Dalfampridine extended-release tablets are marketed and sold in the U.S. under the trade name AMPYRA by Acorda. In

 

18



Table of Contents

 

January 2010, the FDA approved AMPYRA as a treatment to improve walking in patients with multiple sclerosis (“MS”) as demonstrated by an increase in walking speed. It is the first and, currently, only product to be approved for this indication. Prolonged-release fampridine tablets are marketed and sold outside the U.S. under the trade name FAMPYRA by Biogen Idec. In July 2011, the European Medicines Agency (“EMA”) conditionally approved FAMPYRA in the EU for the improvement of walking in adults with MS. This authorization was renewed as of July 2013. The product incorporates our oral controlled release technology. AMPYRA and FAMPYRA are manufactured by us.

 

BYDUREON

 

BYDUREON (exenatide extended-release for injectable suspension) was approved by the FDA in January 2012, and received marketing authorization in the EU in June 2011, for the treatment of type 2 diabetes. BYDUREON, a once-weekly formulation of exenatide, the active ingredient in BYETTA, uses our polymer-based microsphere injectable extended-release technology. From August 2012 until February 2014, Bristol-Myers Squibb Company (“Bristol-Myers”) and AstraZeneca co-developed and marketed BYDUREON through their diabetes collaboration. In February 2014, AstraZeneca assumed sole responsibility for the development and commercialization of BYDUREON. In March 2014, AstraZeneca announced FDA approval of the BYDUREON Pen 2 mg. AstraZeneca announced that they plan to make the BYDUREON Pen available for patients in the second half of 2014.

 

VIVITROL

 

VIVITROL is a once-monthly injectable medication approved by the FDA for the treatment of alcohol dependence in April 2006 and for the prevention of relapse to opioid dependence, following opioid detoxification, in October 2010. The medication uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every four weeks. We developed, and currently market and sell, VIVITROL in the U.S., and Cilag sells VIVITROL in Russia and the Commonwealth of Independent States. The Russian regulatory authorities approved VIVITROL for the treatment of alcohol dependence in 2008 and for the treatment of opioid dependence in 2011.

 

Key Development Programs

 

We also have several proprietary and partnered product candidates in various stages of development, as discussed below.

 

Aripiprazole Lauroxil

 

We are studying aripiprazole lauroxil for the treatment of schizophrenia. Aripiprazole lauroxil is designed to provide once-monthly dosing of a medication that converts in vivo into aripiprazole, a molecule that is commercially available under the name ABILIFY. Aripiprazole lauroxil is our first product candidate to leverage our proprietary LinkeRx technology.

 

In April 2014, we announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia and presented the comprehensive data from the phase 3 study in June 2014. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (“PANSS”) total scores, compared to placebo, which was the prespecified primary endpoint in the study. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression — Improvement scale (“CGI-I”) versus placebo. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Based on the positive results from this phase 3 study, we plan to submit an NDA to the FDA in the third quarter of 2014.

 

In January 2014, we announced plans to commence clinical testing of aripiprazole lauroxil two-month, a new product candidate for the treatment of schizophrenia. If approved, aripiprazole lauroxil would be the first and only long-acting atypical antipsychotic medication dosed every two months.

 

Samidorphan /ALKS 33

 

Samidorphan, formerly referred to as ALKS 33, is a proprietary oral opioid modulator characterized by limited hepatic metabolism and durable pharmacologic activity in modulating brain opioid receptors. A phase 2 study of samidorphan in alcohol dependence was completed, and samidorphan is currently being evaluated as a component of ALKS 5461 and ALKS 3831.

 

ALKS 5461

 

ALKS 5461 is a proprietary combination of samidorphan and buprenorphine that we are developing for the treatment of

 

19



Table of Contents

 

major depressive disorder (“MDD”) in patients who have an inadequate response to standard antidepressant therapies. In March 2014, we announced the initiation of the pivotal clinical development program for ALKS 5461. The comprehensive pivotal program, named FORWARD (Focused On Results With A Rethinking of Depression), includes a total of 12 studies, including three core phase 3 efficacy studies and nine supportive studies. We announced initiation of two core efficacy studies in June 2014, and announced initiation of the third core efficacy study in July 2014. The core efficacy studies are designed to evaluate the safety and efficacy of ALKS 5461 as adjunctive treatment in patients with MDD and incorporate sophisticated design features. The FORWARD pivotal program will include studies to evaluate the long-term safety, dosing, pharmacokinetic profile and human abuse liability of ALKS 5461. The three core efficacy studies will utilize state-of-the-art methodologies intended to reduce the impact of clinically meaningful placebo response. Data from these three core efficacy studies are expected in 2016.

 

ALKS 3831

 

ALKS 3831 is a proprietary investigational medicine designed as a broad-spectrum treatment for schizophrenia. ALKS 3831 is composed of samidorphan in combination with the established antipsychotic drug olanzapine, which is generally available under the name ZYPREXA. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, and to have utility in patients with schizophrenia exacerbated by alcohol use. We expect to complete enrollment of an ongoing phase 2 study designed to assess ALKS 3831’s magnitude of effect on olanzapine-induced weight gain, in 2014. In June 2014, we announced initiation of a second phase 2 study, which is a randomized, double-blind, active-controlled study that will assess ALKS 3831’s efficacy, safety and tolerability in treating patients with schizophrenia and alcohol use, compared to olanzapine. We expect to have topline results from this study in mid 2017

 

MMF Prodrug ALKS 8700

 

ALKS 8700 is an oral, novel and proprietary molecule in development for the treatment of MS, designed to rapidly and efficiently convert to monomethyl fumarate (“MMF”) in the body and to offer differentiated features as compared to the currently marketed dimethyl fumarate, TECFIDERA. In July 2014, we announced that we had initiated a randomized, double-blind phase 1 study of ALKS 8700, designed to evaluate the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups.

 

ALKS 7106

 

ALKS 7106 is our novel and proprietary small-molecule investigational product derived from our opioid modulator platform. ALKS 7106 is a potent oral opioid analgesic designed for the treatment of pain with intrinsically low potential for abuse and overdose death, which are two liabilities associated with opioid medicines. We expect to file an IND and initiate clinical studies in mid 2014.

 

RDB 1419

 

RDB 1419 is a proprietary biologic cancer immunotherapy investigational product based on interleukin-2 and its receptors. RDB 1419 was engineered using our proprietary fusion protein technology platform to modulate the natural mechanism of action of a biologic. We expect to conduct IND-enabling activities for RDB 1419 in 2014.

 

Other

 

A phase 3 clinical research program for a three-month formulation of INVEGA SUSTENNA (paliperidone palmitate 3-month formulation), an investigational treatment for symptoms of schizophrenia in adults, was initiated by Janssen Research & Development, LLC (“Janssen R&D”) in 2012. In March 2014, Janssen R&D announced that, following an Independent Data Monitoring Committee recommendation based on positive efficacy, it halted early a phase 3 clinical study of paliperidone palmitate 3-month formulation. Janssen R&D has stated that, following a final analysis of the study and discussions with the FDA, it plans to file an NDA with the FDA for paliperidone palmitate 3-month formulation by the end of 2014 and that the study results will be presented at a future medical congress and will also be submitted for publication in a peer-reviewed journal. This investigational product is being developed by Janssen Pharmaceutica, NV, as licensee to our proprietary technology for nanoparticles.

 

In July 2014, Janssen Pharmaceuticals, Inc. announced the submission of a supplemental New Drug Application (“sNDA”) to the FDA seeking a label change that, if approved, is expected to include new data showing delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic INVEGA SUSTENNA (paliperidone palmitate) compared to selected oral antipsychotic therapies in the treatment of schizophrenia. Janssen Pharmaceuticals, Inc. also announced the submission of sNDAs to the FDA for once-monthly INVEGA SUSTENNA for approval to treat schizoaffective disorder as either monotherapy or adjunctive therapy in May 2014.

 

20



Table of Contents

 

AstraZeneca is developing line extensions for BYDUREON for the treatment of type 2 diabetes, including a dual-chamber pen device, and weekly and monthly suspension formulations using our proprietary technology for extended-release microspheres. AstraZeneca stated that they expect the Committee for Medicinal Products for Human Use (“CHMP”) to issue its opinion on the BYDUREON dual-chamber pen in the fourth quarter of 2014, and that they plan to file for approval of the dual- chamber pen in Japan. AstraZeneca expects to file for approval of the BYDUREON once-weekly suspension in the U.S. and EU in 2015.

 

Patents and Proprietary Rights

 

In June 2014, we announced that the United States Patent and Trademark Office (“USPTO”) had issued Notices of Allowance, which are issued after the USPTO makes a determination that a patent can be granted from an application, for four of our key development program candidates for the treatment of CNS disorders as follows:

 

Aripiprazole lauroxil: The USPTO issued a Notice of Allowance for U.S. Patent Application 13/607,066, entitled “Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders.” We expect this patent to issue within the next few months and expire no earlier than September 2030.

 

ALKS 5461: The USPTO issued a Notice of Allowance for U.S. Patent Application 13/715,198, entitled “Compositions of Buprenorphine and a Mu Antagonist.” We expect this patent to issue within the next few months and expire no earlier than December 2032.

 

ALKS 3831: On July 15, 2014, following our announcement of the Notice of Allowance relating to ALKS 3831, the USPTO issued U.S. Patent No. 8,778,960, entitled “Methods for Treating Antipsychotic-Induced Weight Gain.” We expect this patent to expire no earlier than August 2031.

 

ALKS 7106: The USPTO issued a Notice of Allowance for U.S. Patent Application 14/169,305, entitled “4-Hydroxybenzomorphans.” We expect this patent to issue within the next few months and expire no earlier than November 2025.

 

Results of Operations

 

Manufacturing and Royalty Revenues

 

Manufacturing fees are earned for the manufacture of products under arrangements with our collaborators when product is shipped to them at an agreed upon price. Royalties are earned on our collaborators’ sales of products that incorporate our technologies. Royalties are generally recognized in the period the products are sold by our collaborators. The following table compares manufacturing and royalty revenues earned in the three and six months ended June 30, 2014, as compared to the three and six months ended June 30, 2013:

 

 

 

Three Months Ended

 

Change

 

Six Months Ended

 

Change

 

 

 

June 30,

 

Favorable/

 

June 30,

 

Favorable/

 

(In millions)

 

2014

 

2013

 

(Unfavorable)

 

2014

 

2013

 

(Unfavorable)

 

Manufacturing and royalty revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

RISPERDAL CONSTA

 

$

26.9

 

$

34.4

 

$

(7.5

)

$

55.5

 

$

65.2

 

$

(9.7

)

INVEGA SUSTENNA/XEPLION

 

33.1

 

21.8

 

11.3

 

54.1

 

36.6

 

17.5

 

AMPYRA/FAMPYRA

 

19.5

 

19.9

 

(0.4

)

40.1

 

44.5

 

(4.4

)

RITALIN LA/FOCALIN XR

 

10.9

 

11.2

 

(0.3

)

20.6

 

21.8

 

(1.2

)

BYDUREON

 

8.8

 

5.4

 

3.4

 

16.5

 

10.1

 

6.4

 

Other

 

31.2

 

27.1

 

4.1

 

54.8

 

88.5

 

(33.7

)

Manufacturing and royalty revenues

 

$

130.4

 

$

119.8

 

$

10.6

 

$

241.6

 

$

266.7

 

$

(25.1

)

 

The decrease in RISPERDAL CONSTA manufacturing and royalty revenues in the three and six months ended June 30, 2014 as compared to the three and six months ended June 30, 2013 was primarily due to a 10% and 9% decrease in royalty revenues, respectively, and an 16% and 13% decrease in the number of units shipped to Janssen, respectively. Janssen’s end-market sales of RISPERDAL CONSTA were $302.0 million and $612.0 million for the three and six months ended June 30, 2014, respectively, and $336.0 million and $671.0 million for the three and six months ended June 30, 2013, respectively. Under our RISPERDAL CONSTA supply and license agreements with Janssen, we earn manufacturing revenues at 7.5% of Janssen’s unit net sales price of RISPERDAL CONSTA and royalty revenues at 2.5% of Janssen’s end-market net sales of RISPERDAL CONSTA.

 

21



Table of Contents

 

The increase in INVEGA SUSTENNA/XEPLION royalty revenues in the three and six months ended June 30, 2014, as compared to the three and six months ended June 30, 2013, was due to an increase in Janssen’s end-market sales of INVEGA SUSTENNA/XEPLION. During the three and six months ended June 30, 2014, Janssen’s end-market sales of INVEGA SUSTENNA/XEPLION were $394.0 million and $767.0 million, respectively, as compared to $290.0 million and $574.0 million in the three and six months ended June 30, 2013, respectively. Under our INVEGA SUSTENNA/XEPLION agreement with Janssen, we earn royalty revenues on end-market net sales of INVEGA SUSTENNA/XEPLION of: 5% up to the first $250 million in calendar-year net sales; 7% on calendar-year net sales of between $250 million and $500 million; and 9% on calendar-year net sales exceeding $500 million. The royalty rate resets at the beginning of each calendar year to 5%.

 

The increase in BYDUREON royalty revenues in the three and six months ended June 30, 2014, as compared to the three and six months ended June 30, 2013, was due to an increase in end-market sales of BYDUREON by AstraZeneca. During the three and six months ended June 30, 2014, our estimate of AstraZeneca’s end-market sales of BYDUREON was $103.0 million and $199.0 million, respectively, as compared to $66.9 million and $127.9 million sold under the Bristol-Myers and AstraZeneca diabetes collaboration in the three and six months ended June 30, 2013, respectively.

 

Included in other manufacturing and royalty revenues during the six months ended June 30, 2013 was $30.0 million of IP license revenue unrelated to key development programs.

 

Product Sales, net

 

Our product sales, net consist of sales of VIVITROL in the U.S. to wholesalers, a specialty distributor and specialty pharmacies. The following table presents the adjustments deducted from VIVITROL product sales, gross to arrive at VIVITROL product sales, net for sales of VIVITROL in the U.S. during the three and six months ended June 30, 2014 and 2013:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

(In millions)

 

2014

 

% of Sales

 

2013

 

% of Sales

 

2014

 

% of Sales

 

2013

 

% of Sales

 

Product sales, gross

 

$

31.6

 

100.0

%

$

24.3

 

100.0

%

$

57.5

 

100.0

%

$

44.6

 

100.0

%

Adjustments to product sales, gross:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medicaid rebates

 

(2.8

)

(8.9

)%

(1.8

)

(7.4

)%

(4.4

)

(7.7

)%

(3.3

)

(7.4

)%

Product discounts

 

(2.2

)

(7.0

)%

(1.7

)

(7.0

)%

(4.1

)

(7.1

)%

(2.7

)

(6.1

)%

Chargebacks

 

(2.1

)

(6.6

)%

(1.7

)

(7.0

)%

(3.6

)

(6.3

)%

(3.0

)

(6.7

)%

Co-pay assistance

 

(1.6

)

(5.1

)%

(1.3

)

(5.3

)%

(2.9

)

(5.0

)%

(2.1

)

(4.7

)%

Product returns

 

(0.9

)

(2.8

)%

0.1

 

0.4

%

(1.4

)

(2.4

)%

(0.2

)

(0.4

)%

Other

 

(0.4

)

(1.2

)%

(0.5

)

(2.1

)%

(2.4

)

(4.2

)%

(1.3

)

(2.9

)%

Total adjustments

 

(10.0

)

(31.6

)%

(6.9

)

(28.4

)%

(18.8

)

(32.7

)%

(12.6

)

(28.3

)%

Product sales, net

 

$

21.6

 

68.4

%

$

17.4

 

71.6

%

$

38.7

 

67.3

%

$

32.0

 

71.7

%

 

The increase in product sales, gross for the three and six months ended June 30, 2014, as compared to the three and six months ended June 30, 2013, was due to a 24% and 26% increase in the number of units sold, respectively, as well as a 5% price increase, effective April 1, 2014. The increase in Medicaid rebates, chargebacks and co-pay assistance were all primarily due to the increase in VIVITROL gross product sales. The increase in other adjustments during the six months ended June 30, 2014 was primarily due to a $1.4 million charge in the three months ended March 31, 2014 against product sales, net, related to a limited VIVITROL recall for a needle clog issue.

 

Costs and Expenses

 

Cost of Goods Manufactured and Sold

 

 

 

Three Months Ended

 

Change

 

Six Months Ended

 

Change

 

 

 

June 30,

 

Favorable/

 

June 30,

 

Favorable/

 

(In millions)

 

2014

 

2013

 

(Unfavorable)

 

2014

 

2013

 

(Unfavorable)

 

Cost of goods manufactured and sold

 

$

43.3

 

$

46.0

 

$

2.7

 

$

82.1

 

$

94.0

 

$

11.9

 

 

The decrease in cost of goods manufactured and sold during the three months ended June 30, 2014 as compared to the three months ended June 30, 2013, was primarily due to a 16% decrease in the number of RISPERDAL CONSTA units shipped to Janssen, partially offset by a 9% increase in shipments of our legacy products.  The decrease in cost of goods manufactured and sold during the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was primarily due to a 13%

 

22



Table of Contents

 

decrease in the number of RISPERDAL CONSTA units shipped to Janssen and a 13% decrease in shipments of our legacy products.

 

Research and Development Expense

 

For each of our R&D programs, we incur both external and internal expenses. External R&D expenses include costs related to clinical and non-clinical activities performed by contract research organizations (“CROs”), consulting fees, laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. We track external R&D expenses for each of our development programs; however, internal R&D expenses are not tracked by individual program as they benefit multiple programs or our technologies in general.

 

The following table sets forth our external R&D expenses relating to our individual Key Development Programs and all other development programs, and our internal R&D expenses by the nature of such expenses:

 

 

 

Three Months Ended

 

Change

 

Six Months Ended

 

Change

 

 

 

June 30,

 

Favorable/

 

June 30,

 

Favorable/

 

(In millions)

 

2014

 

2013

 

(Unfavorable)

 

2014

 

2013

 

(Unfavorable)

 

External R&D Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Key development programs:

 

 

 

 

 

 

 

 

 

 

 

 

 

ALKS 5461

 

$

20.7

 

$

1.8

 

$

(18.9

)

$

31.7

 

$

4.1

 

$

(27.6

)

Aripiprazole lauroxil

 

5.8

 

4.7

 

(1.1

)

13.2

 

14.9

 

1.7

 

ALKS 3831

 

6.0

 

2.3

 

(3.7

)

11.1

 

2.3

 

(8.8

)

ALKS 8700

 

2.3

 

 

(2.3

)

3.8

 

 

(3.8

)

ALKS 7106

 

2.4

 

 

(2.4

)

3.6

 

 

(3.6

)

Other development programs

 

4.2

 

5.2

 

1.0

 

6.7

 

9.7

 

3.0

 

Total external R&D expenses

 

41.4

 

14.0

 

(27.4

)

70.1

 

31.0

 

(39.1

)

Internal R&D expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee-related

 

19.4

 

13.3

 

(6.1

)

36.8

 

27.1

 

(9.7

)

Occupancy

 

1.8

 

1.4

 

(0.4

)

3.4

 

2.7

 

(0.7

)

Depreciation

 

2.0

 

2.2

 

0.2

 

4.1

 

3.7

 

(0.4

)

Other

 

2.6

 

2.6

 

 

4.9

 

4.8

 

(0.1

)

Total internal R&D expenses

 

25.8

 

19.5

 

(6.3

)

49.2

 

38.3

 

(10.9

)

Research and development expenses

 

$

67.2

 

$

33.5

 

$

(33.7

)

$

119.3

 

$

69.3

 

$

(50.0

)

 

These amounts are not necessarily predictive of future R&D expenses. In an effort to allocate our spending most effectively, we continually evaluate the products under development, based on the performance of such products in pre-clinical and/or clinical trials, our expectations regarding the likelihood of their regulatory approval and our view of their commercial viability, among other factors.

 

The increase in expenses related to ALKS 5461 was the result of the initiation and start-up activities associated with the multiple phase 3 studies in 2014. The increase in expenses related to the ALKS 3831 program was due to an ongoing phase 2 study that was initiated in July 2013, and the initiation of a second phase 2 study to investigate the potential utility of ALKS 3831 for patients with schizophrenia exacerbated by alcohol use in 2014. ALKS 8700 and ALKS 7106 were added to our key development program portfolio in 2013. In July 2014, we initiated a phase 1 study for ALKS 8700 and plan to file an IND for ALKS 7106 in mid 2014.  The increase in employee-related expenses was primarily due to an increase in headcount and share-based compensation expense. Expenses incurred under the samidorphan, which was formerly referred to as ALKS 33, and the RDB 1419 program were not material in the three and six months ended June 30, 2014 and 2013.

 

Selling, General and Administrative Expense

 

 

 

Three Months Ended

 

Change

 

Six Months Ended

 

Change

 

 

 

June 30,

 

Favorable/

 

June 30,

 

Favorable/

 

(In millions)

 

2014

 

2013

 

(Unfavorable)

 

2014

 

2013

 

(Unfavorable)

 

Selling, general and administrative expense

 

$

50.7

 

$

32.9

 

$

(17.8

)

$

93.2

 

$

67.6

 

$

(25.6

)

 

The increase in selling, general and administrative (“SG&A”) expense for the three and six months ended June 30, 2014 as compared to the three and six months ended June 30, 2013, was primarily due to a $10.8 million and $14.0 million increase in employee-related expenses, respectively, and a $5.8 million and $9.9 million increase in professional service fees and marketing

 

23



Table of Contents

 

expenses, respectively. The increase in employee-related expenses was primarily due to an increase in share-based compensation of $7.9 million and $10.9 million in the three and six months ended June 30, 2014, respectively, due to an increase in our stock price and an increase in headcount. The increases in professional service fees and marketing expenses were primarily due to an increase in activity related to the anticipated launch of aripiprazole lauroxil and increased marketing activities related to VIVITROL. We expect SG&A expenses to continue to increase in 2014 as launch planning activities accelerate for aripiprazole lauroxil.

 

Amortization of Acquired Intangible Assets

 

 

 

Three Months Ended

 

Change

 

Six Months Ended

 

Change

 

 

 

June 30,

 

Favorable/

 

June 30,

 

Favorable/

 

(In millions)

 

2014

 

2013

 

(Unfavorable)

 

2014

 

2013

 

(Unfavorable)

 

Amortization of acquired intangible assets

 

$

15.1

 

$

12.7

 

$

(2.4

)

$

27.7

 

$

23.0

 

$

(4.7

)

 

The intangible assets being amortized in the three and six months ended June 30, 2014 and 2013 were acquired as part of the acquisition of Elan Drug Technologies (“EDT”) in September 2011. In connection with the acquisition of EDT, we acquired certain amortizable intangible assets with a fair value of $643.2 million, which were expected to be amortized over 12 to 13 years. We amortize our amortizable intangible assets using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. Based on our most recent analysis, amortization of intangible assets included within our consolidated balance sheet at June 30, 2014 is expected to be approximately $60.0 million, $65.0 million, $70.0 million, $70.0 million and $70.0 million in the years ending December 31, 2014 through 2018, respectively.

 

Restructuring

 

On April 4, 2013, we approved a restructuring plan at our Athlone, Ireland manufacturing facility consistent with the evolution of our product portfolio and designed to improve operational performance in the future. The restructuring plan calls for us to terminate manufacturing services for certain older products that are expected to no longer be economically practicable to produce due to decreasing demand from our customers resulting from generic competition. We expect to continue to generate revenues from the manufacturing of these products into the year ending December 31, 2015.

 

As a result of the termination of these services, we began a corresponding reduction in headcount of up to 130 employees. During the three months ended March 31, 2013, we recorded a one-time restructuring charge, expected to be settled in cash payments, consisting solely of severance and outplacement services of $12.3 million.

 

Other Income (Expense), Net

 

 

 

Three Months Ended

 

Change

 

Six Months Ended

 

Change

 

 

 

June 30,

 

Favorable/

 

June 30,

 

Favorable/

 

(In millions)

 

2014

 

2013

 

(Unfavorable)

 

2014

 

2013

 

(Unfavorable)

 

Interest income

 

$

0.3

 

$

0.2

 

$

0.1

 

$

0.8

 

$

0.3